 | |||||||
| lung cancer | |||||||
| 新闻 | |||||||
Ryan Tedford Shares Insights About Sotatercept and Findings From the CADENCE Trial The CADENCE trial showed that sotatercept reduced pulmonary vascular resistance and improved right ventricular function in CPC-PH.
| |||||||
| 查看更多结果 | 修改此快讯 | |||||||
| 您收到此电子邮件是因为您订阅了Google快讯。 |
 以RSS Feed的形式接收此快讯 |
| 发送反馈 |
No comments:
Post a Comment